Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1151404 | 0.86 | TSHR (0.50) | TSHRALDH1A1KDM4EATMTDP1 | |
| SCHEMBL2036985 | 0.83 | TTR (0.45) | TSHRALDH1A1KDM4ETDP1GRIN2D | |
| SCHEMBL27163032 | 0.83 | MAPT (0.38) | ALDH1A1TDP1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL3653489 | 0.82 | HTT (0.33) | TSHRALDH1A1TDP1GRIN2DGRIN3B | |
| SCHEMBL3650227 | 0.81 | MAPT (0.36) | ALDH1A1KDM4ETDP1GRIN2DGRIN3B | |
| SCHEMBL309792 | 0.79 | TDP1 (0.35) | TSHRALDH1A1KDM4EATMTDP1 | |
| SCHEMBL12693888 | 0.79 | POLB (0.38) | TSHRALDH1A1KDM4EATMTDP1 | |
| SCHEMBL1151055 | 0.79 | CYP1A2 (0.40) | TSHRKDM4ETDP1HIF1AMAPT | |
| SCHEMBL24207654 | 0.78 | ATM (0.34) | TSHRALDH1A1ATMTDP1HIF1A | |
| SCHEMBL31650905 | 0.78 | ATM (0.34) | TSHRALDH1A1ATMTDP1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262842-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME LLC | 2024-08-08 | — | — | US | disclosed |
| CN-111166744-B | Use of 4- (benzothiazol-2-yl) arylamine compound for treating gastric cancer | 诺丁汉大学 | 2024-06-25 | — | — | CN | disclosed |
| EP-4329749-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022232318-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-11-03 | — | — | WO | disclosed |
| US-8093406-B2 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | NOVARTIS AG (CH) | 2012-01-10 | — | — | US | disclosed |
| EP-2303857-A1 | CYCLIC SULFONES WITH AMINOBENZYL SUBSTITUTION USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| EP-2190833-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | Novartis Ag (CH) | 2010-06-02 | — | — | EP | disclosed |
| US-20100056490-A1 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| WO-2010003976-A1 | CYCLIC SULFONES WITH AMINOBENZYL SUBSTITUTION USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2010-01-14 | — | — | WO | disclosed |
| WO-2009024615-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054427-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | BRIARD EMMANUELLE | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054427-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | BACE2, BACE1, APP | TSHR 4858/4885ALDH1A1 2720/4885KDM4E 1305/4885 |
| US-20240262842-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | KRAS, NRAS, HRAS | TSHR 4548/4885ALDH1A1 1875/4885KDM4E 3441/4885 |
| US-20100056490-A1 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | BACE2, BACE1, APP | TSHR 4855/4885ALDH1A1 2566/4885KDM4E 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.